A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma
This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Hiroshima, Japan
- Hiroshima University Hospital
-
Kumamoto, Japan
- Kumamoto University Hospital
-
Kyoto, Japan
- Kyoto University Hospital
-
Osaka, Japan
- National Hospital Organization Osaka National Hospital
-
Tokyo, Japan
- Kyorin University Hospital
-
Tokyo, Japan
- National Cancer Center Hospital
-
Tokyo, Japan
- Tokyo Women's Medical University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan
- Nagoya University Hospital
-
-
Kanagawa
-
Sagamihara, Kanagawa, Japan
- Kitasato University Hospital
-
-
Miyagi
-
Sendai, Miyagi, Japan
- Tohoku University Hospital
-
-
Saitama
-
Hidaka, Saitama, Japan
- Saitama Medical University International Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has a histopathologically documented IDH1 mutated WHO grade II glioma according to the 2016 WHO classification.
- Has confirmed IDH1 mutation at the R132 locus by testing at the central laboratory conducted during the screening period.
- Has no prior anticancer treatment (including chemotherapy and radiotherapy) for glioma except craniotomy or biopsy.
- Has at least 1 measurable and non-enhancing lesion.
- Has an interval of at least 90 days from the latest surgery.
- Has no sign of malignant transformation including the appearance of enhancing lesions and/or rapid growth of non-enhancing lesions.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1.
Exclusion Criteria:
- Has had a histopathological diagnosis of WHO grade III or IV glioma.
- Has had a contrast enhancing lesion on brain MRI.
- Has received a prior treatment with any mutant IDH1 inhibitor.
- Has received other investigational products within 28 days before the start of the study drug treatment.
- Has an active infection requiring systemic treatment.
- Has multiple primary malignancies.
- Has a history of clinically significant cardiac disease.
- Is a pregnant or lactating woman.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: DS-1001b
|
250 mg, twice daily, continuous oral administration |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall response rate (ORR) assessed by Independent Efficacy Review Committee
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Number of participants with treatment-emergent adverse events (TEAEs) during the study
Time Frame: Up to 24 months
|
Up to 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Clinical benefit rate
Time Frame: Through the end of the study (up to approximately 6 years)
|
Through the end of the study (up to approximately 6 years)
|
|
Percentage change in tumor volume
Time Frame: Through the end of the study (up to approximately 6 years)
|
Through the end of the study (up to approximately 6 years)
|
|
Time to response
Time Frame: Through the end of the study (up to approximately 6 years)
|
Through the end of the study (up to approximately 6 years)
|
|
Duration of response
Time Frame: Through the end of the study (up to approximately 6 years)
|
Through the end of the study (up to approximately 6 years)
|
|
Time to treatment failure
Time Frame: Through the end of the study (up to approximately 6 years)
|
Through the end of the study (up to approximately 6 years)
|
|
Progression-free survival
Time Frame: Through the end of the study (up to approximately 6 years)
|
Through the end of the study (up to approximately 6 years)
|
|
Overall survival
Time Frame: Through the end of the study (up to approximately 6 years)
|
Through the end of the study (up to approximately 6 years)
|
|
Area under the concentration curve (AUC) for DS-1001a
Time Frame: Cycle 1 Day 1 to Cycle 13 Day 1 (each cycle is 28 days)
|
Cycle 1 Day 1 to Cycle 13 Day 1 (each cycle is 28 days)
|
|
Maximum plasma concentration (Cmax) for DS-1001a
Time Frame: Cycle 1 Day 1 to Cycle 13 Day 1 (each cycle is 28 days)
|
Cycle 1 Day 1 to Cycle 13 Day 1 (each cycle is 28 days)
|
|
Time to maximum plasma concentration (Tmax) for DS-1001a
Time Frame: Cycle 1 Day 1 to Cycle 13 Day 1 (each cycle is 28 days)
|
Cycle 1 Day 1 to Cycle 13 Day 1 (each cycle is 28 days)
|
|
Change from baseline in 2-hydroxyglutarate (2-HG) concentration in patient specimens after treatment with DS-1001b
Time Frame: Through the end of the study (up to approximately 6 years)
|
Through the end of the study (up to approximately 6 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Study Leader, Daiichi Sankyo
Publications and helpful links
General Publications
- Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata N, Muragaki Y, Shinojima N, Kumabe T, Saito R, Motomura K, Mineharu Y, Miyakita Y, Yamasaki F, Matsushita Y, Ichimura K, Ito K, Tachibana M, Kakurai Y, Okamoto N, Asahi T, Nishijima S, Yamaguchi T, Tsubouchi H, Nakamura H, Nishikawa R. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol. 2023 Feb 14;25(2):326-336. doi: 10.1093/neuonc/noac155.
- Arakawa Y, Saito R, Kanemura Y, Mishima K, Koriyama S, Narita Y, Kumabe T, Motomura K, Sugiyama K, Yamasaki F, Mukasa A, Kanamori M, Kuga D, Nagane M, Kakurai Y, Isobe K, Nakamura H. Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naive isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas. Neuro Oncol. 2026 Mar 1;28(3):717-727. doi: 10.1093/neuonc/noaf258.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DS1001-A-J201
- 205339 (Other Identifier: JapicCTI)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.